Jeffrey Eisele - Jan 30, 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Development Officer
Signature
/s/ David Watson, attorney-in-fact for Jeffrey Eisele
Stock symbol
APLS
Transactions as of
Jan 30, 2023
Transactions value $
-$46,587
Form type
4
Date filed
1/31/2023, 03:51 PM
Previous filing
Jan 30, 2023
Next filing
Feb 22, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Sale -$46.6K -883 -1.86% $52.76 46.5K Jan 30, 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sale originated from established 10b5-1 trading plan.